# Timothy C. Mills

> Timothy C. Mills is a Series C investor at Sanderling Ventures backing Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sanderling Ventures](https://shizune.co/investors/profile/sanderling-ventures)
- Location: San Mateo, United States
- Total investments: 9
- Last investment: Jan 2018
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/timothy-mills-phd-93158221/

Timothy C. Mills is a Series C investor at Sanderling Ventures in San Mateo focused on Health Care and Biotechnology. With nearly 20 years of experience in biomedical research and corporate management, Timothy C. Mills joined Sanderling as an operating partner in July 1998, and was promoted to Managing Director in 2000. At Sanderling, Dr. Mills has focused on early stage investments in medical devices, biotherapeutics, and i-Health. He serves Sanderling portfoliocompanies as Director, CEO and Management team member. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific in 1997. From 1994 to 1997, he was a Director for Prograft Medical, a Target affiliate that was acquired by W.L Gore. Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills' previous academic appointments included service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department. Dr. Mills received a Ph.D. in bioengineering from the University of California, Berkeley & San Francisco School of Medicine, a M.S. in electrical engineering and computer science from the University of California, Berkeley, and a B.S. in electrical engineering from the University of Colorado, Boulder.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 22% |
| Biotechnology | 2 | 22% |
| Diabetes | 1 | 11% |
| Medical Device | 1 | 11% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 33% |
| Series B | 2 | 22% |
| Series D | 2 | 22% |
| Series A | 1 | 11% |
| Series E | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Metavention | Metavention develops medical devices to help with interventional therapies for Type 2 diabetes. | $65M | Series C | Jan 08, 2018 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $25M | Series E | Jul 26, 2016 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $30M | Series D | Sep 19, 2012 |  |
| InfraReDx | InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronaryarteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts. | $21M | Series D | Oct 12, 2010 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $15M | Series C | Apr 15, 2009 |  |
| InfraReDx | InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronaryarteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts. | $15.6M | Series C | Jan 22, 2008 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $10M | Series B | Jun 28, 2005 |  |
| InfraReDx | InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronaryarteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts. | $2.8M | Series B | Apr 29, 2005 |  |
| InfraReDx | InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronaryarteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts. | $4.4M | Series A | Aug 05, 2003 |  |

9 of 9 investments shown.

## Co-investors
- [Mayo Clinic Ventures](https://shizune.co/investors/profile/mayo-clinic-ventures) — VC Fund, 4 deals together
- [Accuitive Medical Ventures](https://shizune.co/investors/profile/accuitive-medical-ventures) — VC Fund, 2 deals together
- [Kaiser Permanente Ventures](https://shizune.co/investors/profile/kaiser-permanente-ventures) — VC Fund, 2 deals together
- [Horowitz Group](https://shizune.co/investors/profile/horowitz-group) — VC Fund, 1 deal together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 1 deal together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 1 deal together

## About Sanderling Ventures

VC Fund · San Mateo, United States

Sanderling Ventures is an investment company that specializes in seed and early-stage investments. It also participates in later-stage financings. The firm focuses on new biomedical market opportunities, including emerging technology in the areas such as biotechnology, life sciences, therapeutics and pharmaceuticals, drug delivery, medical devices,and instrumentation; imaging and diagnostics, medical informatics, healthcare information technology; and health care services. It seeks to invest in United States and Canada.Sanderling Ventures was founded by Robert McNeil in 1979 and is headquartered in Sam Mateo, California.

5 contacts available at Sanderling Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Fred Middleton | Managing Director | https://shizune.co/investors/profile/fred-middleton |
| Timothy C. Mills | Managing Director | https://shizune.co/investors/profile/timothy-c-mills |
| Timothy Wollaeger | Managing Director | https://shizune.co/investors/profile/timothy-wollaeger |
| Michael Dixon | Managing Director | https://shizune.co/investors/profile/michael-dixon-6 |
| Paulette Taylor | General Counsel & Principal | https://shizune.co/investors/profile/paulette-taylor |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Timothy C. Mills invest in?

Timothy C. Mills invests primarily in Health Care, Biotechnology and Diabetes startups, most often at Series C and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Timothy C. Mills last invest?

The most recent investment recorded for Timothy C. Mills closed in Jan 2018. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co